DOSAGE INDEX / SINGLE
BPC-157
Research, reported schedules and supply planning.
Review BPC-157 tendon experiments, human knee-pain reports, the two-person safety pilot and FDA findings, with clear limits on clinical claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 200–600 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
The source explicitly extrapolates from preclinical models. This does not establish a routine human regimen.
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–14 | 0.2 mg | Daily |
| Days 15–28 | 0.4 mg | Daily |
| Days 29–56 | 0.6 mg | Daily |
Compare the product label or clinical-study schedule
Preclinical studies and limited human reports; no general human treatment protocol is established by the evidence summarized here.
We do not designate an online BPC-157 cycle as a validated common human dose. The FDA’s 2026 scientific review identified substantial characterization, safety and effectiveness limitations. A dose used in a small exploratory report does not establish a routine treatment schedule.
Reported risks and uncertainties include immunogenicity and peptide impurities. The linked scientific assessment is a dated evidence source, not a statement about every current legal pathway.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
Source example: 56-day planning window: 25.2 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 5 mg | 6 |
| 10 mg | 3 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- Staresinic and colleagues studied transected rat Achilles tendons, with assessments extending to 14 days. They reported favorable mechanical, functional and tissue findings, including greater load to failure and improved Achilles functional index values. The paper also included a separate cultured-tendocyte experiment. [1]
- A 2026 study randomized 32 rats with surgically repaired Achilles injuries into four groups. Four tendons per group were allocated to mechanical testing and four to histological analysis. BPC-157's maximum-load result was numerically higher than control without reaching statistical significance; TB-500 reached significance. The combination did not add benefit over the individual agents. [3]
- A 2021 retrospective report reviewed 17 patients and reached 16 by telephone. Twelve had received BPC-157 alone, with 11 reporting improvement; four had received a combination with TB4, with three reporting improvement. The study had no untreated comparison group and did not use specific tools to measure function, quality of life, stiffness or daily activities. [4]
- FDA's current safety page identifies potential immunogenicity concerns for certain BPC-157 administration routes, peptide-related impurities and characterization difficulties. It states that safety information is absent or limited for proposed routes. [7]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 30 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Staresinic 2003, rat Achilles transection
- Krivic 2006, rat tendon-to-bone injury
- Bicer 2026, repaired Achilles comparison
- Lee and Padgett 2021, retrospective knee report
- Lee and Burgess 2025, two-person safety pilot
- FDA 2026 briefing evaluation
- FDA safety information
- Journal of Pharmacological SciencesFurther reading · Listed in reference bibliography.
- Pharmaceuticals (MDPI)Further reading · Listed in reference bibliography.
- Current Pharmaceutical Design (PMC)Further reading · Listed in reference bibliography.
- Life SciencesFurther reading · Listed in reference bibliography.
- HSS Journal (PubMed)Further reading · Listed in reference bibliography.
- Journal of Orthopaedic ResearchFurther reading · Listed in reference bibliography.
- WHO (NCBI Bookshelf)Further reading · Listed in reference bibliography.
- Johns Hopkins Arthritis CenterGeneral guidance · Listed in reference bibliography.
- ClinicalTrials.govTrial registry · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
- World Journal of Gastroenterology (PMC)Further reading · Listed in reference bibliography.
- BPC-157 Rat and Dog Pharmacokinetics (PubMed)Further reading · Listed in reference bibliography.
Product-label / dose evidence
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.